EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target

Alyssa C Fasciano, Lamyaa Shaban, Joan Mecsas

EcoSal Plus · 31.12.2019 · 8 (2)

DOI: 10.1128/ecosalplus.esp-0032-2018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EcoSal Plus, erschienen am 31.12.2019. Verfasst von Alyssa C Fasciano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program in Immunology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic resistance is a major public health threat that has stimulated the scientific community to search for nontraditional therapeutic targets. Because virulence, but not the growth, of many Gram-negative bacterial pathogens depends on the multicomponent type three secretion system injectisome (T3SSi), the T3SSi has been an attractive target for identifying small molecules, peptides, and monoclonal antibodies that inhibit its function to render the pathogen avirulent. While many small-molecule lead compounds have been identified in whole-cell-based high-throughput screens (HTSs), only a few protein targets of these compounds are known; such knowledge is an important step to developing more potent and specific inhibitors. Evaluation of the efficacy of compounds in animal studies is ongoing. Some efforts involving the development of antibodies and vaccines that target the T3SSi are further along and include an antibody that is currently in phase II clinical trials. Continued research into these antivirulence therapies, used alone or in combination with traditional antibiotics, requires combined efforts from both pharmaceutical companies and academic labs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAnti-Bacterial AgentsClinical Trials as TopicGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansMiceType III Secretion SystemsVirulence

Substanzen

Anti-Bacterial AgentsType III Secretion Systems

Autor:innen und Institutionen

  • Program in Immunology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111.
  • Program in Molecular Microbiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111.
  • Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA 02111.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Fasciano, A. C., Shaban, L., & Mecsas, J. (2019). Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target. EcoSal Plus, 8(2). https://doi.org/10.1128/ecosalplus.esp-0032-2018

Vancouver

Fasciano AC, Shaban L, Mecsas J. Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target. EcoSal Plus. 2019;8(2). doi:10.1128/ecosalplus.esp-0032-2018

BibTeX
@article{Fasciano2019,
  author = {Fasciano, Alyssa C and Shaban, Lamyaa and Mecsas, Joan},
  title = {Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target},
  journal = {EcoSal Plus},
  year = {2019},
  volume = {8},
  number = {2},
  doi = {10.1128/ecosalplus.esp-0032-2018}
}
Kostenlos starten →